Aptose Biosciences Inc.
DelistedCIK 882361fmd_0P1WP5JHZ46NACYX4PK996B5BXManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2015 to Mar 31, 2026, 39 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 8 | 6 | 19 | 17 | 29 | 46 | 25 | 33 | 15 | 11 |
| Total operating expenses | – | 12 | 29 | 27 | 56 | 65 | 43 | 52 | 26 | 25 |
| Interest expense | 0 | – | – | – | – | – | – | – | – | – |
| Interest and investment income | – | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 |
| Other non-operating income (expense) | – | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | (1) |
| Income before taxes | – | (12) | (29) | (26) | (55) | (65) | (42) | (51) | (25) | (25) |
| Income tax expense | – | – | – | – | – | – | – | – | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | (25) | (25) |
| Net income | (14) | (12) | (29) | (26) | (55) | (65) | (42) | (51) | (25) | (25) |